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Summary
Observational studies have identified a number of patient characteristics predictive of subsequent development
of coronary artery disease. Most of these risk factors are modifiable. There are now compelling evidence that
modification of some of these risk factors can prevent progression and promote regression of coronary artery
disease. This article reviews the evidence for the causative role of these risk factors in coronary atherosclerosis,
possible preventive measures and treatment goals. (HK Pract 1997;19:451-465)
f f-i
Introduction
In contrast to the world-wide
trends of declining death rates from
coronary artery disease (CAD), the
mortality rate from ischaemic heart
disease in Hong Kong has been
cl imbing up s teadi ly 1 (Figure 1),
and CAD has a lways been the
second killer. These facts are tragic
in the s ense CAD i s l a r g e l y
preven tab le . A n u m b e r of r isk
factors have been associated with
the subsequen t deve lopment of
CAD. Many of them are modifiable2
(Table 1). It has been shown that
wide-spread application of proven
preventive strategies can result in
significant reduc t ion of CAD
mortality and morbidity. This article
reviews the importance of risk factor
assessment and mod i f i c a t i on for
preventing CAD.
Risk factor assessment
The term risk factor is widely
used to describe those characteristics
found in individuals that have been
* Address for correspondence: Prof C P Lau, Department of Medicine, Queen Mary Hospital, Pokfulam. Hong Kong.
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Figure 1: Mortality rate from acute myocardial infarction and other ischaemic heart disease in Hong
Kong
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Hyperglycemia/diabetes
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Thrombogenic factors
Age
Sex
Family history of CAD or other
atherosclerotic vascular disease at
early age (in men < 55 years, in
women < 65 years)
Personal history of CAD or other
atherosclerotic vascular disease
shown in observational epidemiolog-
ical, autopsy, metabolic and genetic
studies to relate to the subsequent
occurrence of CAD. As mentioned
by Kannel in 1976, "coronary
disease does not really begin with
crushing chest pain, pulmonary
oedema, shock, angina or ventricular
fibrillation but rather with the more
sub t l e signs l ike a poor coronary
risk profile".3
Severa l facts emerged from
these studies. Firstly, risk factors
interact synergistically, that is, in a
multiplicative rather than an additive
manner , to increase markedly the
risk of CAD. Secondly, the
presence of, and the severity of one
or more risk factors, and the
presence of manifest atherosclerosis
dictate the aggressiveness of
intervention. Thirdly, mul t ip le risk
factors interventions result in a
reduction in CAD. Finally, as CAD
takes time to develop, intervention
should ideal ly begin at an early age
for best effects.
In the subsequent d iscuss ion ,
the evidence for the causative role
of the modifiable and avoidable risk
factors in CAD is presented,
followed by suggested interventions
and then the recommended targets of
therapy.
(Continued on page 454)
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Hypertension and left
ventricular hypertrophy
Evidence
1. E p i d e m i o l o g i c a l su rveys
indicate that the risk of CAD
and cerebrovascular disease
increases cont inuously with
increasing blood pressure in
both sexes.4
2. A meta-analysis by MacMahon
and colleagues5 of 9 prospective
observational studies involving
over 400 ,000 p a r t i c i p a n t s
showed a strongly posit ive
relationship between both
systolic and diastolic blood
pressure and CAD. The
relat ionship was l inear and
without a threshold effect. It
showed a relative risk compared
to normotensive individuals of
3:1 at the highest pressure.
3. A meta-analysis of randomised
controlled trials comprising
t o t a l l y 37,000 pat ients
convincingly demonstrated that
blood pressure lowering by
drugs reduces the subsequent
cardiovascular mor ta l i ty and
morbidity.6 By maintaining a
mean diastolic blood pressure
difference of 5-6 mmHg
between the treated and control
groups for about 5 years, there
was 14% reduction in the
incidence of fatal or non-fatal
CAD.
4. Benefit of treatment of
hypertension in lowering CAD
mortality extends to individuals
aged 75 years or above.7
5. In the SHEP (Systolic
Hypertension in the Elder ly
Program) Study, it was shown
that treatment of isolated
sys to l ic hype r t ens ion is
beneficial in reducing the
incidence of cardiovascular
complications including stroke,
heart failure and CAD.8
6. Presence of left ventricular
hypertrophy (LVH) is an
independent risk factor for
cardiovascular morbidity and
mortality, particularly for acute
myocardial infarction (AMI),
sudden death and congestive
heart failure.9
7. A report from the Framingham
Heart Study found that subjects
who demonstrated ECG
regression of LVH is associated
with a 25% risk reduction in
cardiovascular events.10
Intervention
1. Non-pharmacological measures
a) w e i g h t r e d u c t i o n in
overweight subjects
b) avoid excessive a lcohol
(not more t h a n 10 -
30 gram/day)
c) regular exercise
d) reduce sodium intake to
not more than 5 gm/day
e) maintain adequate dietary
intake of potassium,
calcium and magnesium.
2. Drug treatment
Treatment goals of hypertension
should include optimal blood
pressure control and prevention
of end-organ damage including
LVH, renal failure, CAD and
stroke. Al though the ear ly
randomized t r i a l s of p r imary
preven t ion of CAD in
asymptomatic subjects have
been conducted principally with
diuretics and beta-blockers, the
beneficial effects probably can
be achieved with the newer
anti-hypertensives. In one non-
randomised study, angiotensin
converting enzyme inh ib i to rs
(ACEIs) may induce a greater
degree of LVH regression than
beta-blockers, while the efficacy
o f d i u r e t i c s a n d c a l c i u m
channel blockers lie somewhere
in between."
Target
B e n e f i t i s d o c u m e n t e d for
lowering diastolic blood pressure to
between 85 to 90 mmHg. The
situation is less certain for systolic
blood pressure goal. An appropriate
aim for systolic blood pressure is
below 140mmHg in midd le -aged
patients and below 160 mmHg in the
e l d e r l y . 1 2 , 1 3 I n p a t i e n t s w i t h
documented CAD, blood pressure
should not be lowered excessively
w h i c h may be a s s o c i a t e d w i t h
greater cardiovascular morbidity (J-
curve hypothesis).
Cigarette smoking
Evidence
There is overwhelming evidence
from o b s e r v a t i o n a l s t u d i e s t h a t
cigarette smoking increases the risk
of cardiovascular disease.
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1. In the British Doctors study, the
overall relative risk of coronary
death was shown to be about
doub led , for both men and
women, with a greater relative
risk at a younger age.14-15
2. Risk increases linearly with the
number of cigarettes consumed,
approaching 5.5 for fatal
cardiovascular events among
heavy smokers.
3. Smoking magnifies the effect of
other risk factors, especially the
plasma cholesterol level,
thereby accelerating athero-
sclerosis.2
4. Sudden cardiac death, especially
in younger men, is strongly
associated with smoking.16
5. Passive smoking is inhalation
of o the r p e o p l e ' s tobacco
smoke. Tobacco smoke consists
of sidestream smoke from the
burning tip of the cigarette and
mains t ream smoke that has
been inhaled and then exhaled
by the smoker. Eighty-f ive
percent of tobacco smoke in a
room is sidestream smoke
wh ich con ta ins a h igher
proportion of toxic gases. Male
and f e m a l e n o n - s m o k e r s
exposed to environmental
tobacco smoke (passive
smoking) have a 30% increased
risk of death from acute
myocardial infarction or CAD.17
6. In the British Doctors study,14,15
excess risk was halved wi th in
the first 2-3 years fol lowing
cessation of smoking, and by
10 years the r i sk level had
r e t u r n e d to tha t of a n o n -
smoker . Ano the r report , 1 8
however, reported a slower rate
of disappearance of risk. In
patients with established CAD,
the r i s k becomes r e d u c e d
within 2-3 years to the level of
those CAD patients who never
s m o k e d . 1 9 A s w o u l d b e
expected, the level to which the
risk drops varies between
individuals and depends on the
amount and dura t ion of
cigarette smoking and the other
risk factors present.
7. Smoking cessation is especially
impor t an t in secondary
prevention. In one observational
study,20 stopping smoking more
t h a n ha lved the n u m b e r of
deaths over a 13-year follow-
up.
8. Continued smoking after bypass
grafting is associated with a
twofold increase in the relative
risk of death and an increase in
non-fatal myocardial infarction
and angina.
Intervention
1. Simply instructing smokers to
stop smoking and giving them a
self-help leaflet during routine
consu l t a t ions by fami ly
physicians can result in a 1-
year quit rate of 5%.21
2. O n e - y e a r c e s s a t i o n ra te
increases to 19-38% with more
intensive intervention, such as
participation of a formal
cessation program.2
3. Demonstration to the smoker of
the level of carbon monoxide in
expired breath was shown to
enhance the effect of advice.22
4. Two large meta-analyses2 3-2 4
have now demonstrated that
nicotine replacement therapies
(nicotine patch or gum) approx-
imately double the cessation
rate. The benefit is greater in
those w i th h i g h l e v e l s o f
nicotine dependence.
Target
Complete cessation.
Elevated l o w - d e n s i t y
lipoprotein (LDL) choles-
terol
Evidence
N u m e r o u s e p i d e m i o l o g i c a l
studies have demonstrated a strong
and graded association between total
cholesterol (60-70% transported in
the LDL f r a c t i o n ) and r i s k of
subsequent CAD events wi th no
th resho ld effect. A number of
controlled trials examining the effect
of cholesterol reduction on angio-
g r a p h i c d o c u m e n t e d s t enosed
atherosclerotic lesions have convinc-
ing ly shown that cho les te ro l
lowering slows down the progres-
sion of these lesions and may even
lead to regression in some of them.
Clinical benefit of LDL choles-
terol r educ t ion is demons t r a t ed
recently in 3 large scale prospective,
randomised controlled trials:
1. West of Scotland Coronary
Prevention Study25
(Continued on page 458)
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A pr imary prevention t r ia l
involving 6,595 middle aged
men with an average baseline
cholesterol of 7.0 mmol/1 (mean
LDL cholesterol level of
4.92 mmol/L) were recruited.
After treatment with pravastatin
40 mg daily for 5 years, there
was a 31% reduc t i on in
incidence of fatal and non-fatal
myocardial infarction compared
to those receiving placebo.
All-cause mortal i ty was also
reduced by 22%.
2. Scand inav ian S imvas ta t in
Survival (4S) Study26
This trial randomised 4,444
patients with a total cholesterol
c o n c e n t r a t i o n of 5.5 -
8 . 0 m m o l / l ( m e a n L D L
cholesterol level of 4.87 mmol/
L) and angina or a previous
m y o c a r d i a l i n f a r c t i o n to
simvastatin or placebo. Over a
mean follow-up period of 5.4
years, there was a mean
reduction in total cholesterol of
25%, and the relative risks of
death from all causes and CAD
were significantly reduced by
30% and 42%, respectively.
3. Cholesterol and Recurrent
Events (CARE) Study27
4 , 1 5 9 p o s t - m y o c a r d i a l
infarct ion patients with total
cholesterol less than 6.2 mmol/l
(mean LDL cholesterol level of
3.56 mmol/L) were randomised
to either pravastatin or placebo.
After 5 years' follow-up shows
that there was a 24% reduction
in the incidence of primary
end-point (CAD death or non-
fatal m y o c a r d i a l i n fa rc t ion ) .
This study also documents a
threshold LDL-cholesterol level
for treatment (> 3.0 mmol/L).
Intervention
1. Achieve ideal body weight.
2. Encourage regular exercise.
3. Limit total fat intake to 20-30%
of total energy intake. Reduce
cholesterol intake to less than
3 0 0 m g / d a y . C u t d o w n
saturated fat consumption to
less than 10% of da i l y total
energy intake.
4. For patients with documented
CAD or asymptomatic persons
at high risk, drug therapy may
be i n i t i a t ed if the above-
mentioned measures fail to
lower c h o l e s t e r o l level
satisfactorily. Four classes of
drugs are available - statins,
resins, fibrates and nicot inic
acid - each with its distinctive
therapeutic profile.28-29 Before
u s i n g these m e d i c a t i o n s i n
other subjects with lower risk
of CAD, the long-term safety of
the d rug , compl i ance of the
i n d i v i d u a l and cost-effective-
ness of the therapy should be
considered.
Target
Based on currently available
data, it wou ld be p ruden t to
recommend a target LDL cholesterol
of 2.6-3.027, 30 m m o l / l for CAD
patients and 3.4-3.72, 25, 30 mmol/l for
high risk asymptomatic subjects.
Reduced h igh-dens i ty
l i p o p r o t e i n ( H D L )
cholesterol
Evidence
1. A meta-analysis3 1 of 4 major
US p r o s p e c t i v e s t u d i e s -
Framingham Heart Study, the
Coronary Primary Prevention
T r i a l , t h e L i p i d R e s e a r c h
Cl in ics Fol low-Up Study and
M u l t i p l e R i sk F a c t o r s
Intervention Trial (MRFIT) -
r e v e a l e d t h a t f o r e a c h
0.025 mmol/l (1 mg/dl) decrease
in HDL cholesterol level , the
risk of CAD increases by 2-3%.
2. A high HDL cholesterol level
appears to confer p ro tec t ion
even when LDL choles te ro l
levels are r e l a t i v e l y h igh .
Converse ly , a r e d u c e d HDL
cholesterol l eve l may be
associated with CAD even
when the LDL cholesterol level
is in the normal range.32
3. Another important parameter in
assessing CAD risk is the total
cholesterol to HDL cholesterol
ratio. A desirable ratio is below
4.5 and the optimal goal is less
than 3.5"
4. In pat ients wi th documented
CAD, there was a m a r k e d l y
reduced survival rate from
subsequen t c a r d i o v a s c u l a r
events wi th HDL choles terol
less t h a n 0 .9 m m o l / l and a
twofold increase in events
compared with a baseline HDL
cholesterol level exceeding
0.9 mmol/l.34
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Intervention
1. Aerobic exercise.
2. Stop smoking.
3. Attain ideal body weight.
4. Nicotinic acid can reduce both
LDL cholesterol and triglycer-
i d e w h i l e r a i s i n g H D L
cholesterol level. However, its
use is frequently limited by side
effects.
5. Most of the data on postmeno-
pausal hormone replacement
therapy are observational.
Proof of its protective effect
against CAD awaits prospective
clinical trials, including the
ongoing Women's Health
I n i t i a t i v e . In high risk
hyperlipidemic women, the use
of combined oestrogen and
progestin preparation may still
be justified since the benefit
from preventing atheromatous
complication may outweigh the
increased risk of cancer.29
6. Whether statins, fibrates and
resins can reduce CAD risk by
raising HDL cholesterol levels
in pat ients with acceptable
levels of LDL cholesterol is yet
untested although the observed
benefits with LDL cholesterol
r educ t ion from most inter-
ventional trials may have been
c o n t r i b u t e d by the co r r e -
sponding elevation of HDL
cholesterol.
7. The consumers of 10-30g of
ethanol daily (1-3 glasses of
wine or 1-3 bottles of beer)
w i l l experience on average a
0.15 to 0.18mmol/l increase in
HDL cholesterol.35 However, it
is well established that levels
of alcohol consumption above
the recommended values are
associated with increased CAD
morbidity and mortality. For
this reason, current guidelines
do not recommend alcohol as a
means of reducing CAD risk.
Target
It is desirable to maintain HDL
cholesterol level not less than
1 mmol/1 in men and not less than
l . l mmol /1 in women w h i l e
keeping the total cholesterol to
HDL-cholesterol ratio between 3.5
to 4.5.
Elevated triglyceride (TG)
Evidence
The relat ionship between TG
and CAD remains controversial. TG
level tends to vary inversely with
HDL cholesterol level. Thus, the
effect of TG d imin i shes or dis-
appears when HDL cholesterol level
is taken into consideration. Some
studies, however, have provided
compelling evidence for TG as an
independent predictor of CAD.
1. The L ip id Research C l i n i c s
Fol low-Up Study reported a
twofold increased mor ta l i ty
with moderate TG elevations
(2.25-4.5 mmol/1) and a 3.5
fold excess death rate with high
TG (over 4.5 mmol/1) in women
aged between 50 to 69 years.
2. In many individuals , elevated
TG levels reflect an underlying
disorder of t r ig lycer ide rich
lipoproteins, very low density
l i p o p r o t e i n (VLDL) and
intermediate density lipoprotein
(IDL) and is associated with an
inc reased p r o d u c t i o n of
particularly atherogenic small,
dense LDL p a r t i c l e s . Not
surpr is ingly , retrospective
analyses of several angiographic
trials36'37 suggest that baseline
levels of TG, IDL and small,
dense LDL are better predictors
of outcome than the LDL
cholesterol level. Benefit of
cholesterol lowering therapy
mostly occurred in patients with
high TG, increased IDL and
small , dense LDL particles
despite similar degree of LDL
cholesterol reduction.
3. Studies in diabetics have also
demonstrated the importance of
TG in CAD as evidenced by the
11-year follow-up of the Paris
Prospective Study38 where TG
was the sole predictor of CAD
death after adjustment for all
other risk factors.
Intervention
1. Achieve ideal body weight.
2. Alcohol restriction.
3. Physical exercise can reduce
TG by act ivat ing l i popro te in
lipase.
4. Stop smoking since it is
associated with 10% elevation
in TG.
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5. Reduce fat intake
Saturated fat should constitute
less than 7% of total calorie
intake. Inappropriately high
energy intake in the form of fat
will cause body tissues such as
adipose tissue and skeletal
muscle to become resistant to
hormones like insu l in . This
w i l l lead to raised TG, low
HDL cholesterol and increased
small, dense LDL particles.
6. Omega-3 fatty acids present in
certain cold-water fish can
lower TG by around 30-50%.
Consuming such fish regularly
is encouraged provided that the
ideal body weight is not
exceeded. In view of potential
side effects like gastrointestinal
upset and weight gain, fish oil
capsules are usually reserved
for exceedingly high TG levels
(over 11 mmol/1). Obviously,
treatment is indicated in the
presence of complicat ing
pancreatitis.
7. Drug treatment with fibrates or
n i c o t i n i c a c i d m a y b e
appropriate in high risk patients
(patients with established CAD,
concomitant hypercholester-
olaemia or familial combined
hyperlipidaemia) if TG is above
2.3 mmol/1. The threshold for
d r u g t h e r a p y w i l l a l so b e
lowered in the presence of low
HDL cholesterol and/or a total
cholesterol to HDL-cholesterol
ratio of 5 or more.
Diabetes mellitus
Evidence
1. In pat ients with n o n - i n s u l i n
dependen t d iabetes me l l i t u s
(NIDDM), coronary mortality is
increased two times in male
and four times in female
patients.39
2. Coronary mortality is increased
threefold to tenfold in patients
with Type I insu l in dependent
diabetes mellitus (IDDM)
compared with that in age-
matched non-diabetic control
subjects.40
3. Diabetes mellitus is associated
wi th decreases in HDL
choles te ro l and increases in
VLDL a n d t r i g l y c e r i d e .
Women with diabetes mell i tus
completely lose their gender-
related protection from CAD.
4. High i n s u l i n concentrations,
whether due to exogenous
i n s u l i n in IDDM patients or
peripheral insu l in resistance in
NIDDM patients, have been
shown to be associated with
CAD independent of other risk
factors.
5. Pat ients with diabetes had a
57% increase in risk of death
even after bypass surgery
according to follow-up data
from the Coronary Artery
Surgery Study (CASS). I t
remains a poor prognostic
f a c t o r i n p a t i e n t s w i t h
established CAD.
Target
Main ta in
2.3 mmol/1.
Intervention
TG level below 1. Weight loss in obese DM
patients will improve insulin
s e n s i t i v i t y a n d lowers t r i -
glyceride levels.
2. Physical exercise wil l decrease
hyperinsulinaemia by reducing
insulin resistance.
3. A diet low in total fat (less
than 30% of calories), saturated
f a t ( l e s s t h a n 10%) , a n d
cholesterol (less than 300 mg/
day) is recommended. Mono-
unsaturated fat predominance
has replaced the high fat and
protein recommendations of the
past.
4. Maximize drug therapy.
Target
In the Diabetes Cont ro l and
Compl ica t ions Trial (DCCT),41
intensive therapy resulted in
decreased incidence of microvascular
complications (retinopathy, micro-
albuminuria and neuropathy). There
is a t r end t o w a r d s r educed
macrovascular complications but it
is not statistically significant. The
role of glucose control in preventing
CAD in NIDDM patients is untested
yet. The ongoing UK Prospective
Diabetes Study may shed some light
on this issue and results should be
available in 1998.
Physical inactivity
Evidence
1. Various observational studies
have found that lack of physical
activity is associated wi th
approximately twice the risk of
dying from CAD.42
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2. There is a strong inverse
association between the risk of
an initial myocardial infarction
a n d p h y s i c a l a c t i v i t y ,
independent of other coronary
risk factors. A 69% reduction
in risk-adjusted myocardial
infarction rate has been
demonst ra ted in subjects
exercising more than 2.2 hours
pe r week, c o m p a r e d w i t h
inactive individuals.43
3. A t h e r o s c l e r o t i c d isease
regression in a degree similar
to that observed in l ipid
lower ing t r ia l s has been
demonstrated by quantitative
angiogram after intense aerobic
exercise training.44
4. A m e t a - a n a l y s i s 4 5 of 22
randomised trials involving
nearly 4,600 patients clearly
showed the benefit of cardiac
rehabilitation after myocardial
in fa rc t ion . Among those
ass igned to an exercise
program, there were significant
reductions in reinfarction rate
(25%), cardiovascular mortality
(22%) and total mortality
(20%).
Intervention
1. Physical activity should be part
of a hea l th p r o m o t i o n and
disease prevention program.
Individuals should be encour-
aged to engage in activities
requiring up to 2,000 Kcal/
week for maximum health
benefits.46 Walking 20 miles
every week is one way to
accomplish this goal. The
same recommendations are
made for both men and women
but more research is needed for
women.
2. Exercise need not be of high
intensity to be beneficial. The
total amount is more important
for health than high-intensity
exercise.
3. It is advisable to perform an
exercise test before recommend-
ing an exercise program to an
asymptomatic sedentary person
above 40 years of age,
particularly if his or her total
CAD risk estimate is high.
4. Exercise recommendations in
patients with established CAD
have to be made only after
comprehensive clinical assess-
ment for which the results of
an exercise stress testing
provide important information
on safety limit.
5. High r i sk pat ients (those
r e c o v e r i n g f r o m a c u t e
myocardial infarction, coronary
artery bypass surgery or
angioplasty) w i l l need an
organized rehabilitation program
w i t h e x e r c i s e t r a i n i n g
performed under cont inuous
electrocardiographic monitoring.
Target
1. Healthy individuals should aim
at consuming 2,000 Kcal every
week through exercise.
2. In patients with CAD, a
progressive and monitored
exercise t ra ining program is
recommended. Maximal heart
rate should be at least 10 beats
per minute below the heart rate
associated with electrocardio-
graphic or clinical evidence of
ischaemia dur ing an exercise
stress test.46
Thrombogenic factors
Evidence
1. Increased CAD has been
associated with:
a) raised levels of fibrinogen,
von Wi l l eb rand factor,
Factor VIIc and homo-
cysteine
b) increased platelet count
and platelet aggregability
c) decreased t i ssue type
plasminogen activator
d) elevated concentration of
lipoprotein(a); a lipoprotein
w i t h a n t i f i b r i n o l y t i c
activity.
2. The value of ant i-platelet
therapy in secondary prevention
was documented in an extensive
meta-analys is by the A n t i -
platelet Trialists ' Collabora-
tion.47 Overall there was a
25% reduction in the incidence
of a subsequent vascular event.
No d i f fe rence was noted
between higher (500-1500 mg/
day) and lower doses (75-
325 mg/day) or between aspirin
monotherapy and adjunctive
use of sulfinpyrazone or dipy-
ridamole.
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3. The v a l u e of a s p i r i n for
p r i m a r y p r e v e n t i o n i s
controversial. Results from the
two largest studies48,49 raised
m u c h deba te . I n g e n e r a l ,
chronic aspirin administration
appears to have some benefits
for hea l thy men at h igher
cardiovascular risk, inc lud ing
those over 50, but appears to
be of limited benefit for healthy
low-risk subjects.
Intervention
1. Exercise, smoking cessation can
lower fibrinogen level.
2. The use of oestrogen and
reduced saturated fat intake can
lower Factor VIIc.
3. Prescribe aspirin to all patients
with CAD unless contrain-
dicated.
Post-menopausal state
Evidence
1. I n c i d e n c e rates of CAD are
substantially higher in men than
i n w o m e n b e f o r e t h e
menopause, at which point the
sex d i f f e r e n t i a l b e g i n s to
diminish.50
2. Among women with premature
m e n o p a u s e , h ighe r ra tes of
CAD are seen compared with
pre-menopausal women of the
same age.51
3. With the minimum daily dose
of conjugated equine oestrogens
o r h u m a n o e s t r o g e n s
recommended for prevention of
bone loss, there would be a
decrease in LDL cholesterol of
between 4 and 10% and an
increase in HDL cholesterol of
around 10 to 15%.52 Recently,
oestrogen associated calcium
antagonist effects, direct actions
of oestrogen on the vessel walls
and oes t rogen associa ted
antioxidant effects have been
reported.53 These could all
offer protection against athero-
sclerosis.
4. Observation studies suggest that
oestrogen replacement in post-
menopausal women results in a
50% reduction in the risk of
d e v e l o p i n g C A D . 5 4 These
studies, however, have been
crit icized5 5 for not adequately
c o n t r o l l e d fo r b iases in
selecting women for treatment.
Intervention
Despite the attractive biochem-
ical changes induced by oestrogen
use, c l in ica l efficacy of post-
menopausal hormone replacement is
sti l l controversial. Worries are still
present concerning whether addition
of progestins in combination therapy
may negate the beneficial effects of
oestrogen 5 6 and also whether
incidence of breast cancer wi l l be
i n c r e a s e d i n t h e l o n g r u n .
Nevertheless, i t may s t i l l be
indicated in women at high risk of
CAD, e s p e c i a l l y i f t h e r e i s
concomitant hyperlipidaemia.57
Obesity
Evidence
1. Inc reased body mass i n d e x
( B M I ) has been shown to be
associated with reduced insulin
sensitivity, increased r isk of
NIDDM,58 raised t r i g l y c e r i d e
and total cholesterol levels, low
HDL cholesterol l eve l 5 9 and
increased blood pressure.12
2 . C o h o r t s t u d i e s h a v e
demons t ra ted tha t obes i ty is
associated with increased r isk
of CAD.60, 61
3. Central obesity is associated
wi th i n s u l i n r e s i s t ance a n d
hypertension. It confers greater
risk of CAD than peripherally
d i s t r i b u t e d fat . M a l e s and
females with a waist: hip ratio
of over 1.0 and 0.8 respectively
are considered most at risk.62
Intervention
Lose weight by reducing energy
intake and /or inc reas ing energy
expenditure.
1. Reduce energy intake
a) Dietary
Take a die t w i t h a d a i l y
energy deficit of between
500 and 1000 Kcal.
b) P h a r m a c o t h e r a p y , e.g.
a p p e t i t e s u p p r e s s a n t s ,
t h e r m o g e n i c a g e n t s ,
b u l k i n g a g e n t s , m a y b e
t r i e d , a l t h o u g h t h e l o n g
t e r m e f f i c a c y of these
treatment m o d a l i t i e s and
their safety are unproved.
c) Procedural interventions,
(e.g. gastric balloon, waist
c o r d , j a w w i r i n g ,
l i p o s u c t i o n ) and o ther
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Risk facter .
ntion
Hypertension < 140/90 mmHg (middle-aged persons)
< 160/90 mmHg (elderly subjects)
Cigarette Smoking Complete cessation
Elevated Low-
Density Lipoprotein
Cholesterol
Low High-Density
Lipoprotein
Cholesterol
< 2.6-3.0 mmol/L for patients withCAD
< 3.4-3.7 mmol/L in high risk
asymptomatic individuals
> 1.0mmol/L in men
> 1.1mmol/L in women
Keep HDL-cholesterol to total
cholesterol ratio between 3.5-4.5
Elevated Triglyceride < 2.3 mmol/L
Diabetes Mellitus
Physical Inactivity
Good blood glucose control (evidence
pending)
Consume 2000 Kcal/week through
aerobic exercise in healthy individuals
Regular exercise (at least 30-40
minutes, 3-4 times weekly) with
intensity guided by exercise ECG
test in established CAD patients
Thrombogenic
Factors
Post-Menopausal
State
Body Mass Index between 20-24.9 kg/in2
Waist to hip ratio <0.9 in men and <0.8
in women
Recommendations
Lifestyle modification - weight control, physical
activity, alcohol moderation and sodium
restriction
Add anti-hypertensive medication if BP is still high
despite above-mentioned measures
Strongly encourage patient and family members to
stop smoking
Provide nicotine replacement therapy and formal
cessation program if needed
Initiate lifestyle change - ideal body weight, regular
physical exercise, dietary restriction
Cholesterol lowering drug
Lifestyle change - ideal body weight, aerobic
exercise and stop smoking
Individual consideration for hormonal replacement
therapy and treatment with statins, fibrates,
nicotinic acid or resins
Lifestyle modification - ideal body weight, alcohol
restriction, regular exercise, reduces fat intake,
stop smoking
Omega-3 fatty acid, fibrates and nicotinic acid
therapy in selected high risk patients
Weight loss for obese patients
Regular exercise
Low fat and cholesterol diet
Optimise insulin or oral hypoglycemic drug therapy
Encourage performing aerobic exercise
Increase in daily lifestyle activities (e.g. using stairs,
household work)
Lifestyle change - regular exercise, stop smoking,
reduce saturated fat intake
Aspirin for all CAD patients unless contraindicated
Oestrogen therapy in post-menopausal women
(individual consideration)
Combined oestrogen-progestogen hormonal
, replacement therapy (individual consideration)
Weight loss by reducing calorie intake and
increasing energy expenditure through exercise
Pharmacotherapy and surgical methods in morbid
obesity patients
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surgical interventions (e.g.
gastroplasty, gastric bypass,
ileal bypass) should be
reserved for morbid obesity
patients.
Increase energy expendi tu re
through exercise
Diet res t r ic t ion must be
accompan ied by inc reas ing
exercise for best effects.
Target
1. The optimal rate of weight loss
is between 0.5 and 1.0 Kg/
week. A more rapid weight
loss is u n d e s i r a b l e due to
accompanying breakdown of
lean body mass.
2. Aim at a body mass index
between 20 to 24.9 Kg/m2.
3. The desirable waist to hip ratio
is less than 0.9 for men and 0.8
for middle-aged women.62,63
Conclusion
While we are putting a lot of
resource on expensive, techno-
logically advanced therapies of
CAD, we shou ld not forget that
preventing CAD from the very
beginning may be much more cost-
effective. Except for some personal/
fami l ia l characteristics, most risk
factors for CAD are either
m o d i f i a b l e or avo idab le . In
contemplating CAD prevention in
any particular person, effort should
be directed to various mentioned
risk factors in a comprehensive
manner. Modest reduct ions in
mul t ip le risk factors are l ikely to
reduce risk more than aggressive
reduction of a single risk factor
while ignoring the others. •
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